Profile_bird

Hey there! merck_serono is using Twitter.

Twitter is a free service that lets you keep in touch with people through the exchange of quick, frequent answers to one simple question: What's happening? Join today to start receiving merck_serono's tweets.

Already using Twitter
from your phone? Click here.

Default_profile_1_bigger
merck_serono

  1. Multiple Sclerosis - Drug Pipeline Analysis and Market Forecasts to 2015 - new ... - PR-inside.com (press release):... http://bit.ly/6thOkE about 6 hours ago from twitterfeed
  2. Genzyme names leaders in key areas - Boston Globe: Genzyme names leaders in key areasBoston GlobeTermeer said Genzy... http://bit.ly/7cJEGD about 11 hours ago from twitterfeed
  3. MERCK KGAA STARTS STIMUVAX PHASE III STUDY IN ASIAN PATIENTS - Trading Markets (press release): MERCK KGAA STARTS S... http://bit.ly/8rezMO about 15 hours ago from twitterfeed
  4. Columbia Laboratories Receives Nasdaq Notice of Non-Compliance with Minimum ... - FOXBusiness: Columbia Laboratorie... http://bit.ly/7SxEpG about 18 hours ago from twitterfeed
  5. Merck KGaA - Financial And Strategic Analysis Review - New Report Published - OfficialWire (press release): Merck K... http://bit.ly/7G8LbY 9:37 AM Dec 10th from twitterfeed
  6. Merck KGaA Starts Stimuvax Phase III Study INSPIRE in Asian Patients with ... - FOXBusiness: Merck KGaA Starts Stim... http://bit.ly/7gKg6J 7:16 AM Dec 10th from twitterfeed
  7. Merck KGaA Starts Stimuvax Phase III Study INSPIRE in Asian Patients with ... - PharmaLive.com (press release): Mer... http://bit.ly/5Yorxf 6:13 AM Dec 10th from twitterfeed
  8. NICE looking favourably on Pfizer's growth therapy Genotropin - Pharma Times: NICE looking favourably on Pfizer's g... http://bit.ly/8RjhFx 3:09 AM Dec 10th from twitterfeed
  9. Merck Serono Initiates KAMPER, the First Pan-European Registry for Patients ... - SYS-CON Media (press release): Me... http://bit.ly/6m7xSN 3:09 AM Dec 10th from twitterfeed
  10. Final Data From Phase 2 Study Confirm High Response Rate Of Micromet's ... - Medical News Today (press release): Fi... http://bit.ly/53RMQG 7:59 PM Dec 9th from twitterfeed
  11. ZymoGenetics Narrows Focus Again; Licenses Anti-IL21 mAb - BioWorld Online: ZymoGenetics Narrows Focus Again; Licen... http://bit.ly/7Y6HFI 5:53 PM Dec 8th from twitterfeed
  12. Science Minister Frankenberg Inaugurates the BioRN Academy in Mannheim - Your-Story.org (press release): Your-Story... http://bit.ly/6XeBt3 9:24 AM Dec 8th from twitterfeed
  13. 2020: A New Drug Delivery Landscape - Drug Discovery & Development: 2020: A New Drug Delivery LandscapeDrug Discove... http://bit.ly/5bvxix 1:19 PM Dec 7th from twitterfeed
  14. TEMIS Unveils First of a Kind Collection Module With Luxid(R) Content Pipeline - PR Newswire (press release): TEMIS... http://bit.ly/7SC33r 5:39 AM Dec 7th from twitterfeed
  15. Data from Phase 1 Study Confirm High Response Rate of Micromet's Blinatumomab ... - PR Newswire (press release): Da... http://bit.ly/6wuLwG 4:27 AM Dec 7th from twitterfeed
  16. Dutch Biotech Company Pepscan Appoints New CEO - Melodika.net: Dutch Biotech Company Pepscan Appoints New CEOMelodi... http://bit.ly/88zDt1 9:39 AM Dec 5th from twitterfeed
  17. Switzerland's 300 richest lose $10 billion in 2009 - The Associated Press: Switzerland's 300 richest lose $10 billi... http://bit.ly/5MCOcf 8:50 PM Dec 3rd from twitterfeed
  18. FDA's Jenkins Sounds Off on Incomplete NDAs - The IN VIVO Blog (blog): The IN VIVO Blog (blog)FDA's Jenkins Sounds ... http://bit.ly/7aPlOV 7:14 PM Dec 3rd from twitterfeed
  19. FDA Rejects Merck KGaA's NDA for MS Treatment - FDA news (subscription): FDA Rejects Merck KGaA's NDA for MS Treatm... http://bit.ly/7JCSPF 3:08 PM Dec 3rd from twitterfeed
  20. Can Novartis Win Race to Launch First Oral Drug for MS? - BNET: BNETCan Novartis Win Race to Launch First Oral Drug... http://bit.ly/6mj2Og 12:30 PM Dec 3rd from twitterfeed